Clinical trial
A Prospective, National, Multi-centric, Non-interventional Study of First Line Osimertinib in Chinese Patients With Locally Advanced/Metastatic，EGFR Mutation-positive NSCLC in Real World Setting
NCT04391283 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, National, Multi-centric, Non-interventional Study of First Line Osimertinib in Chinese Patients With Locally Advanced/Metastatic，EGFR Mutation-positive NSCLC in Real World Setting
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- July 27, 2020
- Completion date
- December 31, 2024
- Enrollment
- 500 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.